885315-96-8
885315-96-8 结构式
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-N3417 | KONGENSIN A Kongensin A | 885315-96-8 | 1 mg | 9500元 |
| 2023/03/20 | HY-N3417 | KONGENSIN A Kongensin A | 885315-96-8 | 5 mg | 20800元 |
常见问题列表
HSP90
RIP3
Apoptosis
Kongensin A (0-15 μM; 6 hours; HT29 cells) treatment induces caspase activation and apoptosis in multiple cancer cell lines in a dosage-dependent manner.
Kongensin A (0-15 μM; 24 hours; HT29 cells) treatment induces the degradation of RIPK1 and oncogenic kinases such as ERBB2, AKT, EGFR, and B-raf, and induces the up-regulation of HSP90A and HSP90B.
Kongensin A covalently binds to cysteine 420 in the middle domain of HSP90 and dissociates HSP90 from its cochaperone CDC37. The HSP90-CDC37 complex is required for RIP3 activation, KA blocks LPS/Smac mimetics/Z-VAD and RIP3 polymerization-induced cell death, in which cell death is dependent on RIP3 but not its upstream kinase RIP1.
Apoptosis Analysis
| Cell Line: | HT29 cells |
| Concentration: | 0 μM, 2.5 μM, 5 μM, 15 μM |
| Incubation Time: | 6 hours |
| Result: | Induced caspase activation and apoptosis in a dosage-dependent manner. |
Western Blot Analysis
| Cell Line: | HT29 cells |
| Concentration: | 0 μM, 2.5 μM, 5 μM, 15 μM |
| Incubation Time: | 24 hours |
| Result: | Induced the degradation of RIPK1 and oncogenic kinases such as ERBB2, AKT, EGFR, and B-raf, and induced the up-regulation of HSP90A and HSP90B. |